Annexon Stock News

Annexon Inc (NASDAQ: ANNX) posted interim data from its ongoing Phase 2 trial of ANX005 in patients with Huntington's disease (HD) who completed the 24-week treatment period.  Annexon is developin

Annexon Inc (ANNX) shares closed 0.4% lower than its previous 52 week low, giving the company a market cap of $458M. The stock is currently up 3.9% year-to-date, down 52.3% over the past 12 months, and down 32.8% over the past five years. This week, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 1.8% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 31.3% The company's stock price performance over the past 12 months lags the peer average by 75.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF

BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classica

BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical

Investors need to pay close attention to Annexon (ANNX) stock based on the movements in the options market lately.

BRISBANE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced safety and dose-response data from its Phase 1 clinical trial of ANX009, the companys subcutaneously administered product candidate that is designed to block the activity of C1q and the entire classical complement pathway. In addition, Annexon reported preclinical data supporting the role of the complement pathway in warm autoimmune hemolytic anemia (wAIHA). The data were presented during two poster sessions at the 63 rd American Society of Hematology (ASH) Annual Meeting & Exposition.

Goldman Sachs Group Inc. lessened its holdings in shares of Annexon, Inc. (NASDAQ:ANNX) by 83.3% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,293 shares of the companys stock after selling 110,896 shares during the quarter. Goldman Sachs Group Inc. owned 0.06% of []

HC Wainwright started coverage on shares of Annexon (NASDAQ:ANNX) in a research report sent to investors on Tuesday morning, Price Targets.com reports. The brokerage issued a buy rating and a $40.00 target price on the stock. Other analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Annexon from a hold []

The shares of Annexon Inc (NASDAQ: ANNX) have received a $40 price target from H.C. Wainwright.

– Dr. Ted Yednock's appointment enhances Annexon's commitment to scientific innovation and pursuit of future programs –

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patient

CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patient

– Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically expanded into additional autoantibody-driven diseases –